Evidence map›Paper›PMID 32912853›Full record

ReviewBMJ global health2020

The cost-effectiveness of hypertension management in low-income and middle-income countries: a review.

Deliana Kostova, Garrison Spencer, Andrew E Moran, Laura K Cobb, Muhammad Jami Husain, Biplab Kumar Datta, Kunihiro Matsushita, Rachel Nugent

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Community health worker-led interventions for hypertension.The Cochrane database of systematic reviews · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deliana KostovaDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Kiv0@cdc.gov.ORCID 0000-0003-2414-0166
Garrison SpencerCenter for Global Noncommunicable Diseases, RTI International, Seattle, Washington, USA.
Andrew E MoranResolve to Save Lives, an initiative of Vital Strategies, New York, New York, United States.
Laura K CobbResolve to Save Lives, an initiative of Vital Strategies, New York, New York, United States.
Muhammad Jami HusainDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Biplab Kumar DattaDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Rachel NugentCenter for Global Noncommunicable Diseases, RTI International, Seattle, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension in low-income and middle-income countries (LMICs) is largely undiagnosed and uncontrolled, representing an untapped opportunity for public health improvement. Implementation of hypertension control strategies in low-resource settings depends in large part on cost considerations. However, evidence on the cost-effectiveness of hypertension interventions in LMICs is varied across geographical, clinical and evaluation contexts. We conducted a comprehensive search for published economic evaluations of hypertension treatment programmes in LMICs. The search identified 71 articles assessing a wide range of hypertension intervention designs and cost components, of which 42 studies across 15 countries reported estimates of cost-effectiveness. Although comparability of results was limited due to heterogeneity in the interventions assessed, populations studied, costs and study quality score, most interventions that reported cost per averted disability-adjusted life-year (DALY) were cost-effective, with costs per averted DALY not exceeding national income thresholds. Programme elements that may reduce cost-effectiveness included screening for hypertension at younger ages, addressing prehypertension, or treating patients at lower cardiovascular disease risk. Cost-effectiveness analysis could provide the evidence base to guide the initiation and development of hypertension programmes.

Indexed as

Developing CountriesHypertensionCost-Benefit AnalysisHumansPovertyQuality-Adjusted Life Yearshealth economicshypertensionreview

Identifiers

PMID32912853
PMCPMC7484861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.